Henrik Gurtler - Novozymes Chairman of the Board
| NVZMF Stock | USD 52.71 1.79 3.28% |
Chairman
Mr. Henrik Gurtler was Chairman of the Board of Directors at Novozymes AS since 2000. He is also Chairman of the Board of Ejendomsmaegler Kim Svane AS. He has experience in managing and working in an international biotechnology company. He holds a MS degree in Chemical Engineering from Danmarks Tekniske Universitet from 1976. since 2000.
| Age | 62 |
| Tenure | 24 years |
| Phone | 45 44 46 00 00 |
| Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Grenville Schoch | AirBoss of America | N/A | |
| Timothy Toppen | AirBoss of America | 57 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 |
Novozymes AS B Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
| Tobias Bjorklund, Head of Investor Relations | ||
| Ester Baiget, Pres CEO | ||
| Kasim Kutay, Director | ||
| Anders Lund, Executive Vice President Household Care & Technical Industries | ||
| Agnete RaaschouNielsen, Director | ||
| Thomas Nagy, Executive VP of Supply Operations | ||
| Pedro Fernandes, Head America | ||
| Joergen Rasmussen, Independent Director | ||
| Andrew Fordyce, Executive VP of Food and Beverages | ||
| Lena Halskov, Director, Employee Representative | ||
| Tue Micheelsen, VP Marketing | ||
| Sebastian Sderberg, VP Acquisitions | ||
| Martin Riise, Head of Investor Relations | ||
| Peder Nielsen, CEO and Pres | ||
| Prisca HavranekKosicek, CFO | ||
| HeinzJuergen Bertram, Independent Director | ||
| Benny Loft, CFO and Executive VP | ||
| Anders Knudsen, Director, Employee Representative | ||
| Lena Olving, Independent Director | ||
| Mathias Uhlen, Independent Director | ||
| Graziela Malucelli, Supply Operations | ||
| Patricia Malarkey, Director | ||
| Henrik Gurtler, Chairman of the Board | ||
| Per Falholt, Consultant | ||
| Kim Stratton, Director | ||
| Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
| Lena Holskov, Director, Employee Representative | ||
| Morten Rasmussen, Sustainability People | ||
| Thomas Bomhoff, Head of Investor Relations | ||
| Lars Green, Director | ||
| MSc MSc, Ex CFO | ||
| Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 222.86 M | |||
| Shares Owned By Insiders | 8.04 % | |||
| Shares Owned By Institutions | 42.30 % | |||
| Price To Earning | 33.38 X | |||
| Price To Book | 6.19 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |